A chronological record of peer-reviewed Thymosin Alpha-1 research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly Thymosin Alpha-1works" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: Dendritic Cell & T-Cell Activation. Primary indications investigated: Immune modulation, Hepatitis B treatment, Cancer immunotherapy adjuvant, Vaccine enhancement.
RCT of thymosin alpha-1 in hospitalized COVID-19 patients with severe pneumonia, measuring immune recovery and mechanical ventilation duration.
Pilot study of thymosin alpha-1 combined with anti-PD-1 checkpoint inhibitor in advanced melanoma and lung cancer.
Comprehensive review of thymosin alpha-1 clinical data spanning over 100 clinical trials in hepatitis, cancer, and immune deficiency.
Comprehensive safety review of thymosin alpha-1 across >50 clinical trials encompassing >1000 patients over 30+ years.
Study of thymosin alpha-1 effects on thymic architecture, T-cell output, and immune reconstitution in aged mice.
Mechanistic study of thymosin alpha-1 effects on pro-inflammatory and anti-inflammatory cytokine production in T-cells and macrophages.
Study examining thymosin alpha-1 effects on CD4+ recovery in advanced HIV patients initiating antiretroviral therapy.
Meta-analysis of 15 controlled trials examining thymosin alpha-1 efficacy in chronic hepatitis B, measuring HBsAg clearance and seroconversion.
Mechanistic study of thymosin alpha-1 effects on dendritic cell phenotype, maturation markers, and T-cell stimulatory capacity.
RCT of thymosin alpha-1 adjunctive therapy in septic patients, measuring immune reconstitution and 28-day mortality.
Pilot study of thymosin alpha-1 with gp100 melanoma peptide vaccine in advanced melanoma patients, measuring immune responses and tumor burden.
RCT of thymosin alpha-1 combined with interferon-alpha in chronic hepatitis C, measuring sustained virological response.
Study of thymosin alpha-1 adjunctive therapy in cancer patients undergoing chemotherapy, accelerating CD4 recovery.
Study demonstrating thymosin alpha-1 adjuvant effects when co-administered with hepatitis B vaccine, enhancing both antibody and cell-mediated immunity.
Preliminary study of thymosin alpha-1 in lupus patients, examining immunological markers and clinical response.
Mechanistic study characterizing thymosin alpha-1 cell surface receptor and downstream signaling pathways in T-cells and monocytes.
Pharmacokinetic study measuring thymosin alpha-1 serum levels, half-life, and tissue accumulation following parenteral administration.
Early comprehensive review of thymosin alpha-1 discovery and effects on T-cell development and immune function in various immunodeficiency states.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Thymosin Alpha-1 is L4 (Strong Clinical Evidence): multiple controlled human clinical trials with replicable data. Treat each study as one data point, not a conclusion.
PeptideMark indexes 113 studies on Thymosin Alpha-1: 45 human studies, 30 animal studies, 20 in-vitro, and 18 reviews. The current evidence level is L4 — strong clinical evidence.
The earliest indexed peer-reviewed study on Thymosin Alpha-1 in the PeptideMark library was published in 1971 (Journal of Experimental Medicine). Research activity has continued through 2021.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Published research activity on Thymosin Alpha-1 has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.